CATALINA HEALTH RESOURCE®

PMI Distribution Pilot Proposal & Considerations


Designing Pilot Programs to Distribute Patient Medication Information
The Brookings Institution
February 23, 2011

Agenda

- Catalina Health Resource
- Pilot Program Design
- Medication Selection
- Measurement
- Next Steps

Introduction to Catalina Health Resource

Catalina Health Resource is a division of Catalina Marketing Corporation, headquartered in St. Petersburg, Florida



Distribution Pilot: Program Design (proposed)

Collaboration among FDA/Brookings/Stakeholder organizations to:

- Select medication(s) for PMI development
- Align objectives/goals/measurement

CHR Pilot Execution, including:


- Use of CHR Retail Pharmacy network to print pilot PMI
- Align participation from select CHR Retail Pharmacy partner(s) to participate in pilot
- Create triggering logic to integrate pilot PMI content into Rx fill workflow
- Pilot PMI to replace 'legacy' documents (CMI, Medication Guide, etc.)
- Provide pilot program measurements

Estimate pilot start 90 days after:

Finalization of PMI content for selected medications, and

Finalization of CHR Retail Partner commitment


Pilot Process Flow




PMI content delivery

- CHR technology 'maps' PMI content to specific NDC
- Pilot PMI content prints at time Rx is processed in pharmacy

- Content to be distributed to patient with other pharmacy content (receipts, health tips, etc.)
- Message content supports 'drive-to-web' for e-version of PMI





Medication Selection

Select Brand medication(s) from interested stakeholders:

- Eli Lilly
- GSK
- Pfizer
- Others

Considerations:

- Medication dispensed in retail pharmacy settings
- Volume of Rx to enable adequate testing/measurement
 - CHR can query retail pharmacy partner data to determine sample size for candidate medications
- Pilot PMI content created by manufacturer of pilot medication(s)
 - PMI Content review/comment by FDA prior to use in pilot
- Recommend minimal number of medication(s) for pilot (1-4)

Sample Brand Volume (CHR network)

Product	UPSPW	TOTAL PMI PRINTS
ELI LILLY		
CYMBALTA	6.3612	165,390
CIALIS	3.2368	84,157
HUMALOG	1.9252	50,055
STRATTERA	1.2318	32,027
ZYPREXA	1.2595	32,748
GSK		
ADVAIR DISKUS	6.8290	177,555
VENTOLIN HFA	6.2998	163,796
FLOVENT HFA	2.6349	68,507
LOVAZA	1.9355	50,322
AVODART	1.2524	32,561
PFIZER		
LIPITOR	13.5932	353,424
VIAGRA	3.9616	103,002
LYRICA	3.4897	90,731
CELEBREX	3.3937	88,237
CHANTIX	1.4563	37,864

Expected volumes based on 2000 retail store pilot over 13 week time period

Post-Pilot Analysis

- PMI Prints by Drug/NDC
 - Geographic distribution
 - Patient demographics
 - Age ranges
 - Gender
 - New Rx vs. Refill Rx
 - Co-morbid conditions (if applicable)
- Retail Pharmacist surveys (if applicable)
 - Distribution of PMI
 - Rx fill workflow implications
 - Patient attitudes on PMI delivery/content
- Others

Next Steps

Pilot Scope, Definition & Goals:

- Specific pilot objectives, timing, measurement
- Determine funding requirements (as applicable)
- Select PMI pilot medications
- Develop drug-specific content for pilot PMI drugs
 - Single PMI prototype vs. multiple formats
 - Pilot PMI "ready" for use

Pilot Execution

- CHR Retail Partner participation
 - Retail Chain, National reach: proprietary technology/pharmacy system
- Develop triggering mechanism for pilot medications
- Develop PMI pilot software disable 'legacy' printing
- Commence pilot monitor pilot progress

Pilot Measurement/Analysis